Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

453
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

581
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
581
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

380
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
380
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
463
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

385
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
385
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Dissociable somatotopic representations of Chinese action verbs in the motor and premotor cortex.

Scientific reports·2013
Same author

High quantum-yield CdSexS1-x/ZnS core/shell quantum dots for warm white light-emitting diodes with good color rendering.

Nanotechnology·2013
Same author

A novel microfluidic mixer based on dual-hydrodynamic focusing for interrogating the kinetics of DNA-protein interaction.

The Analyst·2013
Same author

Correlation of reorientational jumps of water molecules in bulk water.

Physical review. E, Statistical, nonlinear, and soft matter physics·2013
Same author

Palladium-catalyzed direct arylation of C-H bond to construct quaternary carbon centers: the synthesis of diarylfluorene.

Organic letters·2013
Same author

Strength and fracture behavior of graphene grain boundaries: effects of temperature, inflection, and symmetry from molecular dynamics.

Physical chemistry chemical physics : PCCP·2013

Video Experimental Relacionado

Updated: Sep 10, 2025

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.2K

Papel inmunomodulador del butirato en el asma: mecanismos y potenciales terapéuticos

Chao Liu1, Zhu Zeng2, Mei Chen3

  • 1Department of Integrated Traditional Chinese and Western Clinical Medicine, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Frontiers in immunology
|August 27, 2025
PubMed
Resumen

El butirato, un ácido graso de cadena corta (SCFA), reduce efectivamente la inflamación de las vías respiratorias en el asma mediante la modulación de las células y vías inmunitarias. Se necesita más investigación para la aplicación clínica, centrándose en el suministro y la seguridad.

Palabras clave:
el butiratoDesacetilasa de histonasImunidadÁcidos grasos de cadena cortacélulas linfoides innatas de tipo 2

Más Videos Relacionados

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.5K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

3.9K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.2K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.5K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

3.9K

Área de la Ciencia:

  • Inmunología
  • Microbiología
  • Pulmonología

Sus antecedentes:

  • El asma es una enfermedad inflamatoria crónica de las vías respiratorias con una desregulación inmune compleja.
  • Las terapias biológicas actuales y los corticosteroides tienen limitaciones en el tratamiento eficaz del asma.

Objetivo del estudio:

  • Revisar los mecanismos moleculares del butirato en el alivio de la inflamación asmática.
  • Para explorar el potencial del butirato como agente terapéutico para el asma.
  • Para discutir los desafíos y las direcciones futuras para la traducción clínica.

Principales métodos:

  • Revisión de la literatura sobre los efectos del butirato en las células inmunes y las vías relevantes para el asma.
  • Análisis del eje intestino-pulmonar en el contexto de las funciones inmunomoduladoras del butirato.
  • Integración de los conocimientos sobre la red de butirato en el asma.

Principales resultados:

  • El butirato suprime la activación excesiva de las células linfoides innatas de tipo 2 (ILC2s) y las células T auxiliares 2 (Th2).
  • El butirato inhibe la degranulación de los mastocitos y modula la señalización mediada por los receptores.
  • La modulación epigenética y las interacciones del eje intestino-pulmonar contribuyen a los efectos antiinflamatorios del butirato.

Conclusiones:

  • El butirato es prometedor en el manejo del asma al dirigirse a las vías inflamatorias clave.
  • Las intervenciones basadas en la microbiota y la modulación inmune dirigida ofrecen un enfoque dual para el tratamiento del asma.
  • La traducción clínica requiere abordar los desafíos en la entrega, la biodisponibilidad y la seguridad, con innovaciones como los nano-portadores y los probióticos.